Introduction: Breast cancer is a prevalent malignancy affecting both men and women. It is characterized by abnormal cell growth and division within the breast tissue, often forming tumors. The most common types include ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and invasive lobular carcinoma (ILC).
Various factors contribute to breast cancer risk, including genetics, lifestyle, and hormonal factors. Genetic mutations, such as in BRCA1 and BRCA2 genes, can significantly increase susceptibility. Environmental factors like obesity, alcohol consumption, and lack of physical activity may also play a role.
Early detection through regular screenings and prompt treatment are crucial for improving outcomes. Treatment options vary depending on the stage and type of breast cancer and may include surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, or immunotherapy.
Ongoing research aims to better understand the molecular mechanisms underlying breast cancer, identify new therapeutic targets, and improve treatment outcomes. Advances in genetic testing, imaging techniques, and personalized medicine are contributing to enhanced care for breast cancer patients.
Methods: In this research, the important polymorphisms were selected from the NCBI database, and the initial evaluation was based on the number of citations and the population value of 2 and above.
Side effects of domestic and imported drugs available in Iran were collected and all information was entered into MegaGene application (which is a pharmacogenetics software).
Results: In Endoxyna, Brescu, Cybrin, Reximed, Docetaxel, Cyclophosphamide, Cisplatin, Toremifene, Fluorouracil and Paclitaxel medicines, Gastric adenocarcinoma, Inflammation, Hair loss, Nausea, Vomiting and Squamous cell lung carcinoma can be based on genetics.
Conclusion: It is better for people who are suffering from breast cancer to undergo tests to detect these SNPs, by identifying them, they can choose the most effective medicine with the least side effects.
Keywords: Breast Cancer, Pharmacogenetic, MegaGene, BRCA1, BRCA2